现代肿瘤医学
現代腫瘤醫學
현대종류의학
JOURNAL OF MODERN ONCOLOGY
2014年
9期
2118-2120
,共3页
童刚领%王芬%陈晓秋%彭安%申东兰%王树滨
童剛領%王芬%陳曉鞦%彭安%申東蘭%王樹濱
동강령%왕분%진효추%팽안%신동란%왕수빈
转移性乳腺癌%卡培他滨%维持化疗%疗效%毒副反应
轉移性乳腺癌%卡培他濱%維持化療%療效%毒副反應
전이성유선암%잡배타빈%유지화료%료효%독부반응
metastatic breast cancer%capecitabine%maintenance chemotherapy%therapeutic efficacy%toxicity
目的:探讨转移性乳腺癌含卡培他滨联合方案一线化疗后继续卡培他滨维持化疗的疗效和毒副反应。方法:入组20例转移性乳腺癌患者,一线采用多西他赛/吉西他滨/长春瑞滨联合卡培他滨化疗6个周期,疗效评价无进展的患者采用卡培他滨维持化疗持续到疾病进展或出现不能耐受毒副反应为止。结果:一线治疗CR 1例,PR 7例,SD 12例,卡培他滨平均维持化疗周期为10个周期。中位PFS为12.2个月,中位TTP为7.7个月,中位OS为20.2个月。主要毒副反应为手足综合征、骨髓抑制、腹泻等,均可控制。结论:卡培他滨可作为转移性乳腺癌的维持治疗,可改善患者生存,毒副反应轻。
目的:探討轉移性乳腺癌含卡培他濱聯閤方案一線化療後繼續卡培他濱維持化療的療效和毒副反應。方法:入組20例轉移性乳腺癌患者,一線採用多西他賽/吉西他濱/長春瑞濱聯閤卡培他濱化療6箇週期,療效評價無進展的患者採用卡培他濱維持化療持續到疾病進展或齣現不能耐受毒副反應為止。結果:一線治療CR 1例,PR 7例,SD 12例,卡培他濱平均維持化療週期為10箇週期。中位PFS為12.2箇月,中位TTP為7.7箇月,中位OS為20.2箇月。主要毒副反應為手足綜閤徵、骨髓抑製、腹瀉等,均可控製。結論:卡培他濱可作為轉移性乳腺癌的維持治療,可改善患者生存,毒副反應輕。
목적:탐토전이성유선암함잡배타빈연합방안일선화료후계속잡배타빈유지화료적료효화독부반응。방법:입조20례전이성유선암환자,일선채용다서타새/길서타빈/장춘서빈연합잡배타빈화료6개주기,료효평개무진전적환자채용잡배타빈유지화료지속도질병진전혹출현불능내수독부반응위지。결과:일선치료CR 1례,PR 7례,SD 12례,잡배타빈평균유지화료주기위10개주기。중위PFS위12.2개월,중위TTP위7.7개월,중위OS위20.2개월。주요독부반응위수족종합정、골수억제、복사등,균가공제。결론:잡배타빈가작위전이성유선암적유지치료,가개선환자생존,독부반응경。
Objective:To investigate the curative effect and toxicity of capecitabine maintenance chemotherapy af-ter the first-line capecitabine-based combination chemotherapy for patients with metastatic breast cancer(MBC). Methods:This study enrolled into 20 chemotherapy-naive MBC patients.They received 6 cyceles of docetaxel/gem-citabine/vinorelbine and capecitabine chemotherapy,and patients who responded to the themotherapy were assigned to capecitabine maintenance chemotherapy until disease progression or intolerable toxicity.Results:Patients were evalua-ted for the first-line therapy efficacy.The patients who acquired CR,PR and SD were 1,7 and 12.The median of ten cycles of the capecitabine maintenance chemotherapy were completed in 20 patients.The median progression free sur-vival time was 12.2 months.The median time to progression was 7.7 months.The median overall survival time was 20.2 months.The most common toxicity included hand -foot syndrome,myelosuppression,diarrhea.Conclusion:Capecitabine maintenance chemotherapy is benefit in survival in MBC patients,and with low toxicity.